AXL Gene Editing


Our promise to you:
Guaranteed product quality, expert customer support.


AXL Gene Editing    

AXL (also known as Ark, Tyro7 and Ufo) is a founding member of the TAM (TYRO3-AXL-MER) receptor tyrosine kinase (RTK) family, originally isolated from chronic myeloid leukemia cells. The AXL gene is located on chromosome 19q13.2 and encodes a 140 kDa protein with transforming ability.

Structurally, AXL contains two immunoglobulin-like domains (Ig) and two fibronectin III domains in the extracellular region, a single-pass transmembrane domain, and an intracellular protein-tyrosine kinase domain. AXL can be activated in two ways: ligand-dependent dimerization (typically by vitamin K-dependent protein Gas6), or ligand-independent dimerization.

Upon activation by the ligand, AXL binds and induces PI3-kinase acid phosphorylation; as well as GRB2, PLCG1, LCK, and PTPN11. Other downstream substrate candidates for AXL include CBL, NCK2, SOCS1, and TNS2. AXL recruitment of GRB2 and PI3K regulatory subunits leads to downstream activation of AKT kinase. Gas6/AXL signaling plays a role in various processes, such as preventing apoptosis, endothelial cell survival during acidification, optimal cytokine signaling during human natural killer cell development, liver regeneration, neuronal survival and migration, platelet activation or thrombotic regulation response. It also plays an important role in inhibiting Toll-like receptor (TLR)-mediated innate immune responses.

Overexpression and activation of AXL can promote cell proliferation, chemoresistance, invasion and metastasis in several human cancers such as lung, breast and pancreatic cancers (Figure 1). And several studies have shown that overexpression of AXL may lead to differences in drug resistance between targeted and traditional chemotherapy regimens in different models, currently. However, the mechanism of acquired resistance to AXL overexpression in vivo is not known. Prospective clinical studies combining AXL expression as predictive biomarkers for drug response and novel therapeutic targets are necessary.

 Mechanisms of AXL activation in cancerFigure 1: Mechanisms of AXL activation in cancer (Erinn B. Rankin. 2016)

AXL Gene Editing Service

CRISPR/Cas9 PlatformCB, a global leading biotechnological company specializing in gene editing, is dedicated to offering comprehensive CRISPR/Cas9 gene editing services and products to a wide range of genomics researchers. With deep gene editing knowledge and extensive experience in experimental operation and data processing, we can help you effectively control target genes deleted, inserted or point mutated in vivo or in vitro using CRISPR/Cas9 technology.

  • AXL Gene Editing Cell Line Generation

Based on our platform, we have successfully implemented AXL CRISPR/Cas9 gene edited in both easy-to-transfect cell lines and hard-to-transfect cells. To support your projects, we will offer you full-length custom AXL gene editing service from strategy design to final stable cells.

Our AXL gene editing cell line generation services include

➢ Strategy design
➢ gRNA design and synthesis
➢ Transfect the cell lines you're interested
➢ Select the high expression cells and sort monoclonal cell
➢ Validate the knockout/knockin/point mutation of AXL by PCR and sequencing
➢ Produce cryogenic preserved vials of stable cells and a final report

Cell lines we offered

➢ Blood Lineage Cells (RAW264.7, HMC1.2, K562, U937 etc.)
➢ Cancer Cell Lines (HEK293, HEK293T, Hela, MCF7, Neuro2a, HepG2, U87, etc.)
➢ Stem Cells (iPSC)
➢ Other Cell Lines (NIH3T3, MCF10, HEME, SW10 etc.)

  • AXL Gene Editing Animal Model Generation

CRISPR/Cas9 PlatformCB also has extensive experience in incorporating CRISPR/Cas9 technology into animal models, which have been fully recognized by our clients. Tell us your needs, we provide a one-stop-shop AXL CRISPR/Cas9 gene editing animal service and guarantee at least 2 founders or 3 F1 animals with shorter turnaround time and lower price.

Our AXL gene editing animal model generation services include:

➢ AXL gene conventional knockout animals
➢ AXL gene conditional knockout animals
➢ AXL point mutation animals
➢ AXL knockin animals

Alternative species: mouse, rat, rabbit, zebrafish, C. elegans, etc.

CRISPR/Cas9 PlatformCB is devoted to providing the best gene editing services and products for academic research, biotech research and pharmaceutical drug discovery with excellent quality management and quality assurance capacity. To accelerate the achievement of your research goals, our gene editing expert team provides you with custom CRISPR/Cas9 services for any specific gene to help you solve problems encountered during your research. If you have any questions, please feel free to contact us.

Related Products at CRISPR/Cas9 PlatformCB

CLKO-1297AXL KO Cell Lysate-HeLaInquiry
CSC-RT1447Human AXL Knockout Cell Line-HeLaInquiry


  1. Erinn B. Rankin & Amato J. Giaccia. The Receptor Tyrosine Kinase AXL in Cancer Progression. Cancers (Basel). 2016; 8(11):103.
  2. Xiaoliang Wu. et al. AXL kinase as a novel target for cancer therapy. Oncotarget. 2014; 5(20):9546–9563.
  3. Haley Axelrod & Kenneth J. Pienta. Axl as a mediator of cellular growth and survival. Oncotarget. 2014; 5(19):8818–8852.
  4. Yingying Shen. et al. Axl inhibitors as novel cancer therapeutic agents. Life Sciences. 2018; 198:99-111.
For research use only. Not intended for any clinical use.


Verification code